+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

United States Proton Therapy Market, Patient Numbers by 14 Types of Cancer, Reimbursement Policy, Patients Treated at Proton Therapy Centers

  • ID: 4807902
  • Report
  • Region: United States
  • 147 pages
  • Renub Research
1 of 4

FEATURED COMPANIES

  • Elekta
  • IBA
  • Varian Medical Systems
  • MORE

United States is the hub of proton therapy industry where various advanced and children specialist centers and preferential facilities are available for the child. In United States, currently 31 proton therapy centers are operational, and many centers are in the constructional phase and planning phase. Proton therapy centers are growing at a rapid pace in United States as its cancer incidences are raising and there are more patients eligible for treatment than actually resources available for them. Proton therapy is one of the advanced techniques of radiotherapy which produces optimal amount of radiation or pinpoint radiation to kill tumor and mitigate radiation exposure to healthy tissues or cells. The potential of United States Proton Therapy Market is expected to be more than USD 16 Billion by the end of year 2025. But the actual market is merely 10% of the potential market due to demand-supply mismatch.

Proton therapy is a non-invasive procedure that is used for the treatment of multiple cancers like CNS Cancer, Head & Neck Cancer, Prostate Cancer, Breast Cancer and Lung Cancer etc. People across the world are looking for the non-invasive procedure because of its effectiveness and painless outcome. The clinical benefit of using proton therapy is its minimal side effects because proton therapy affects less radiation to healthy tissues or cells.

Besides, proton therapy can be an effective treatment for recurrent tumors. Proton therapy is one of the effective treatments for pediatric patients rather than conventional radiotherapy and surgery that include various risks and complications. Additionally, children body is prone to the re-occurrence of cancer and proton therapy plays an essential role by preventing from re-occurrence. The survival rate of proton therapy is nearly 90 percent which is far better than the traditional technique to treat cancer.

In this report, we have studied the market in two parts a) Actual Market and b) Potential Market. The report also talks about the list of all operational and Proton Therapy centers going to open in future; Economics of proton therapy including reimbursement policies. Proton Therapy revenues from 3 companies (IBA, Varian Medical Systems, Elekta) has also been studied in the report.

1. Actual Market is the current market which is already present
2. Potential Market is the market which can be achieved; but it has yet not been achieved due to demand and supply gap. At present only a few proton therapy centers are available that can treat a limited number of patients each year

Patient Numbers for the Treatment of Proton Therapy in United States

In this report, we have portrayed proton therapy patients into two parts; potential patients and actual one. We have also categorized the proton therapy patient numbers on the basis of cancer type into 14 sections; Central Nervous System Tumors, Intraocular Melanomas, Pituitary Neoplasms, Base of Skull / Axial Skeleton, Head and Neck, Lung Cancers, Retroperitoneal Sarcoma, Pediatric (Up to Age 18), Gastrointestinal Tract, Urinary Tract, Female Pelvic Organs, Prostate Cancer, Breast Cancer and Other.

Proton Therapy Market for 14 Types of Cancer in United States

The proton therapy market is divided into two parts; potential proton therapy market and actual proton therapy market. This report studies the 14 cancer types proton therapy market Retroperitoneal Sarcoma, Central Nervous System Tumors, Pituitary Neoplasms, Intraocular Melanomas, Lung Cancers, Base of Skull / Axial Skeleton, Gastrointestinal Tract, Pediatric (Up to Age 18), Urinary Tract, Head and Neck, Breast Cancer, Female Pelvic Organs, Prostate Cancer, and Other.

According to the publisher , the more patients of cancer would get proton therapy treatment in United States due to rising prevalence of cancer and an increasing number of the advanced proton therapy center. Additionally, increasing technological development in Proton therapy and increasing efficiencies will further boost the market of proton therapy in United States.

Number of Patients Treated in each Proton Therapy Center of United States

In this report, we have done a full assessment of proton therapy center of United States with their treatment capabilities and technology used. Currently, there are 31 operational centers for proton therapy in United States, and XX centers are in construction phase and XX are in planning phase. In this report we have provided complete patients number treated with proton therapy by each proton therapy center of United States.

Reimbursement Policy Insights

Here, we have done an in-depth analysis of reimbursement policies in United States. Here, we have fragmented the reimbursement policy into two parts; the first one is by patient’s perspective, and the second one is by manufacturer, stakeholder and institutional perspective.

Key Companies Covered

1. IBA (Overview, Sales Analysis)
2. Varian Medical Systems (Overview, Sales Analysis)
3. Elekta (Overview, Sales Analysis)

United States Proton Therapy Market & Patient Numbers has been analyzed from two viewpoints

  • Actual & Potential Market
  • Actual & Potential Number of Patients Treated

14 Types of Cancer - Patient Numbers & Market

1. Central Nervous System Tumors Cancer
2. Pituitary Neoplasms Cancer
3. Intraocular Melanomas Cancer
4. Lung Cancers
5. Base of Skull / Axial Skeleton Cancer
6. Gastrointestinal Tract Cancer
7. Pediatric (Up to Age 18) Cancer
8. Urinary Tract Cancer
9. Head and Neck Cancer
10. Breast Cancer
11. Female Pelvic Organs Cancer
12. Prostate Cancer
13. Retroperitoneal Sarcoma Cancer
14. Other Cancer

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Elekta
  • IBA
  • Varian Medical Systems
  • MORE

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market (Actual & Potential) - United States Proton Therapy Market (2009 - 2025)
4.1 Actual Proton Therapy Market
4.2 Potential Proton Therapy Market

5. Number of Patients - United States Proton Therapy (2009 - 2025)
5.1 Actual Numbers
5.2 Potential Numbers

6. Cancer Types - Patients Number in United States Proton Therapy (2009 - 2025)
6.1 Central Nervous System Tumors
6.2 Intraocular Melanomas Cancer
6.3 Pituitary Neoplasms Cancer
6.4 Base of Skull / Axial Skeleton Cancer
6.5 Head and Neck Cancer
6.6 Lung Cancer
6.7 Retroperitoneal Sarcoma Cancer
6.8 Pediatric Cancer Cases (Up to Age 18)
6.9 Gastrointestinal Tract Cancer
6.10 Urinary Tract Cancer
6.11 By Female Pelvic Organs Cancer
6.12 Prostate Cancer
6.13 Breast Cancer
6.14 Other Cancer

7. Cancer Types - United States Proton Therapy Market (2009 - 2025)
7.1 Central Nervous System Tumors
7.2 Intraocular Melanomas Cancer
7.3 Pituitary Neoplasms Cancer
7.4 Base of Skull / Axial Skeleton Cancer
7.5 Head and Neck Cancer
7.6 Lung Cancer
7.7 Retroperitoneal Sarcoma Cancer
7.8 Pediatric Cancer (Up to Age 18)
7.9 Gastrointestinal Tract Cancer
7.10 Urinary Tract Cancer
7.11 Female Pelvic Organs Cancer
7.12 Prostate Cancer
7.13 Breast Cancer
7.14 Other Cancer

8. United States - List of Proton Therapy Centers
8.1 Operating Proton Therapy Centers
8.2 Under-Construction Therapy Centers
8.3 Planning Proton Therapy Centers

9. By Centers - Number of Proton Therapy Patients Treated
9.1 Loma Linda (LLUMC) Proton Therapy Center (2008 - 2016)
9.2 UCSF - CNL Proton Therapy Center (2008 - 2015)
9.3 Boston (NPTC) Proton Therapy Center (2008 - 2016)
9.4 Bloomington (MPRI, 2) Proton Therapy Center (2008 - 2014)
9.5 Houston (MD Anderson) Proton Therapy Center (2008 - 2016)
9.6 UFPTI Jacksonville Proton Therapy Center (2008 - 2016)
9.7 Oklahoma City (ProCure PTC) Proton Therapy Center (2009 - 2017)
9.8 CDH Warrenville Proton Therapy Center (2010 - 2016)
9.9 Philadelphia (Upenn) Proton Therapy Center (2011 - 2016)
9.10 Hampton (HUPTI) Proton Therapy Center (2012 - 2016)
9.11 New Jersey (ProCure PTC) Proton Therapy Center (2012 - 2016)
9.12 Seattle (SCCA ProCure PTC) Proton Therapy Center (2013 - 2016)
9.13 St. Louis (S. Lee King PTC) Proton Therapy Center (2013 - 2016)
9.14 Provision Center for Proton Therapy, Knoxville, TN (2014 - 2016)
9.15 San Diego (Scripps PTC) (2014 - 2017)
9.16 Shreveport (Willis Knighton) Proton Therapy Center (2014 - 2017)
9.17 Jacksonville (Ackerman CC) Proton Therapy Center (2015 - 2016)
9.18 Rochester (Mayo PBTC) Proton Therapy Center (2015 - 2016)
9.19 Brunswick (Laurie PC) Proton Therapy Center (2015)
9.20 Irving (Texas Center for PT) Proton Therapy Center (2015 - 2017)
9.21 Memphis (St. Jude PTC) Proton Therapy Center (2015 - 2017)
9.22 Phoenix (Mayo PBTC) Proton Therapy Center (2016)
9.23 Baltimore (Maryland PTC) Proton Therapy Center (2016)
9.24 Cincinnati (Children's PTC) Proton Therapy Center (2016)
9.25 Orlando (Orlando Health PTC) Proton Therapy Center (2016)
9.26 Cleveland (UH Sideman PTC) Proton Therapy Center (2016)

10. Proton Therapy - Reimbursement Policies
10.1 Proton Therapy Reimbursement Policies for Patients
10.2 Proton Therapy Reimbursement for Institutions, Stakeholders and Manufacturers

11. Components of a Standard Proton Therapy Center
11.1 Proton Accelerator
11.1.1 Synchrotrons (example: LLUMC at Loma Linda)
11.1.2 Cyclotrons (example: MGH Boston)
11.1.3 Synchrocyclotrons (examples: Orsay, Uppsala)
11.1.4 Linacs (Rome)
11.1.5 H-minus Synchrotrons
11.1.6 Separated Sector Cyclotrons
11.1.7 Super-conducting Cyclotrons
11.1.8 Fast Cycling Synchrotron
11.2 Beam Transport System
11.3 Beam Delivery System
11.3.1 The Passive Scattering Technique
11.3.2 Beam Scanning
11.4 Nozzle
11.4.1 Single Scattering
11.4.2 Double Scattering
11.4.3 Uniform Scanning Nozzle
11.4.4 Pencil Scanning Nozzle
11.5 Treatment Planning System
11.6 Image Viewers
11.7 Patient Positioning System (PPS)
11.8 Human Resource

12. Company Analysis (2014 - 2025)
12.1 IBA Proton Therapy
12.1.1 Sales Analysis
12.2 Varian Medical Systems
10.2.2 Sales Analysis
12.3 Elekta
12.3.1 Sales Analysis

13. Driving Factors
13.1 Technology Advancement
13.1.1 Next-Generation Proton Technique
13.2 Growing Incidence of Cancer Patients in United States

14. Challenges
14.1 Requires Huge Investment
14.2 Operations Challenges

List of Figures:
Figure 2 1: United States - Proton Therapy Market (Million US$), 2009 - 2018
Figure 2 2: United States - Forecast for Proton Therapy Market (Million US$), 2019 - 2025
Figure 2 3: United States - Potential Proton Therapy Market (Million US$), 2009 - 2018
Figure 2 4: United States - Forecast for Potential Proton Therapy Market (Million US$), 2019 - 2025
Figure 3 1: United States - Patient Treated with Proton Therapy (Number), 2009 - 2018
Figure 3 2: United States - Forecast for Patient Treated with Proton Therapy (Number), 2019 - 2025
Figure 3 3: United States - Potential Candidate for Proton Therapy (Number), 2009 - 2018
Figure 3 4: United States - Forecast for Potential Candidate for Proton Therapy (Number), 2019 - 2025
Figure 4 1: United States - Proton Therapy Patient by Central Nervous System Tumors (Number), 2009 - 2018
Figure 4 2: United States - Forecast for Proton Therapy Patient by Central Nervous System Tumors (Number), 2019 - 2025
Figure 4 3: United States - Proton Therapy Patient by Intraocular Melanomas Cancer (Number), 2009 - 2018
Figure 4 4: United States - Forecast for Proton Therapy Patient by Intraocular Melanomas Cancer (Number), 2019 - 2025
Figure 4 5: United States - Proton Therapy Patient by Pituitary Neoplasms Cancer (Number), 2009 - 2018
Figure 4 6: United States - Forecast for Proton Therapy Patient by Pituitary Neoplasms Cancer (Number), 2019 - 2025
Figure 4 7: United States - Proton Therapy Patient by Base of Skull / Axial Skeleton Cancer (Number), 2009 - 2018
Figure 4 8: United States - Forecast for Proton Therapy Patient by Base of Skull / Axial Skeleton Cancer (Number), 2019 - 2025
Figure 4 9: United States - Proton Therapy Patient by Head and Neck Cancer (Number), 2009 - 2018
Figure 4 10: United States - Forecast for Proton Therapy Patient by Head and Neck Cancer (Number), 2019 - 2025
Figure 4 11: United States - Proton Therapy Patient by Lung Cancer (Number), 2009 - 2018
Figure 4 12: United States - Forecast for Proton Therapy Patient by Lung Cancer (Number), 2019 - 2025
Figure 4 13: United States - Proton Therapy Patient by Retroperitoneal Sarcoma Cancer (Number), 2009 - 2018
Figure 4 14: United States - Forecast for Proton Therapy Patient by Retroperitoneal Sarcoma Cancer (Number), 2019 - 2025
Figure 4 15: United States - Proton Therapy Patient by Pediatric Cancer (Number), 2009 - 2018
Figure 4 16: United States - Forecast for Proton Therapy Patient by Pediatric Cancer (Number), 2019 - 2025
Figure 4 17: United States - Proton Therapy Patient by Gastrointestinal Tract Cancer (Number), 2009 - 2018
Figure 4 18: United States - Forecast for Proton Therapy Patient by Gastrointestinal Tract Cancer (Number), 2019 - 2025
Figure 4 19: United States - Proton Therapy Patient by Urinary Tract Cancer (Number), 2009 - 2018
Figure 4 20: United States - Forecast for Proton Therapy Patient by Urinary Tract Cancer (Number), 2019 - 2025
Figure 4 21: United States - Proton Therapy Patient by Female Pelvic Organs Cancer (Number), 2009 - 2018
Figure 4 22: United States - Forecast for Proton Therapy Patient by Female Pelvic Organs Cancer (Number), 2019 - 2025
Figure 4 23: United States - Proton Therapy Patient by Prostate Cancer (Number), 2009 - 2018
Figure 4 24: United States - Forecast for Proton Therapy Patient by Prostate Cancer (Number), 2019 - 2025
Figure 4 25: United States - Proton Therapy Patient by Breast Cancer (Number), 2009 - 2017
Figure 4 26: United States - Forecast for Proton Therapy Patient by Breast Cancer (Number), 2019 - 2025
Figure 4 27: United States - Proton Therapy Patient by Other Cancer (Number), 2009 - 2018
Figure 4 28: United States - Forecast for Proton Therapy Patient by Other Cancer (Number), 2019 - 2025
Figure 5 1: United States - Proton Therapy Market by Central Nervous System Tumors (Million US$), 2009 - 2018
Figure 5 2: United States - Forecast for Proton Therapy Market by Central Nervous System Tumors (Million US$), 2019 - 2025
Figure 5 3: United States - Proton Therapy Market by Intraocular Melanomas Cancer (Million US$), 2009 - 2018
Figure 5 4: United States - Forecast for Proton Therapy Market by Intraocular Melanomas Cancer (Million US$), 2019 - 2025
Figure 5 5: United States - Proton Therapy Market by Pituitary Neoplasms Cancer (Million US$), 2009 - 2018
Figure 5 6: United States - Forecast for Proton Therapy Market by Pituitary Neoplasms Cancer (Million US$), 2019 - 2025
Figure 5 7: United States - Proton Therapy Market by Base of Skull / Axial Skeleton Cancer (Million US$), 2009 - 2018
Figure 5 8: United States - Forecast for Proton Therapy Market by Base of Skull / Axial Skeleton Cancer (Million US$), 2019 - 2025
Figure 5 9: United States - Proton Therapy Market by Head and Neck Cancer (Million US$), 2009 - 2018
Figure 5 10: United States - Forecast for Proton Therapy Market by Head and Neck Cancer (Million US$), 2019 - 2025
Figure 5 11: United States - Proton Therapy Market by Lung Cancer (Million US$), 2009 - 2018
Figure 5 12: United States - Forecast for Proton Therapy Market by Lung Cancer (Million US$), 2019 - 2025
Figure 5 13: United States - Proton Therapy Market by Retroperitoneal Sarcoma Cancer (Million US$), 2009 - 2018
Figure 5 14: United States - Forecast for Proton Therapy Market by Retroperitoneal Sarcoma Cancer (Million US$), 2019 - 2025
Figure 5 15: United States - Proton Therapy Market by Pediatric Cancer (Million US$), 2009 - 2018
Figure 5 16: United States - Forecast for Proton Therapy Market by Pediatric Cancer (Million US$), 2019 - 2025
Figure 5 17: United States - Proton Therapy Market by Gastrointestinal Tract Cancer (Million US$), 2009 - 2018
Figure 5 18: United States - Forecast for Proton Therapy Market by Gastrointestinal Tract Cancer (Million US$), 2019 - 2025
Figure 5 19: United States - Proton Therapy Market by Urinary Tract Cancer (Million US$), 2009 - 2018
Figure 5 20: United States - Forecast for Proton Therapy Market by Urinary Tract Cancer (Million US$), 2019 - 2025
Figure 5 21: United States - Proton Therapy Market by Female Pelvic Organs Cancer (Million US$), 2009 - 2018
Figure 5 22: United States - Forecast for Proton Therapy Market by Female Pelvic Organs Cancer (Million US$), 2019 - 2025
Figure 5 23: United States - Proton Therapy Market by Prostate Cancer (Million US$), 2009 - 2018
Figure 5 24: United States - Forecast for Proton Therapy Market by Prostate Cancer (Million US$), 2019 - 2025
Figure 5 25: United States - Proton Therapy Market by Breast Cancer (Million US$), 2009 - 2018
Figure 5 26: United States - Forecast for Proton Therapy Market by Breast Cancer (Million US$), 2019 - 2025
Figure 5 27: United States - Proton Therapy Market by Other Cancer (Million US$), 2009 - 2018
Figure 5 28: United States - Forecast for Proton Therapy Market by Other Cancer (Million US$), 2019 - 2025
Figure 10 1: Global - IBA Proton Therapy Sales (Million US$), 2014 - 2018
Figure 10 2: Global - Forecast for IBA Proton Therapy Sales (Million US$), 2019 - 2025
Figure 10 3: Global - Varian Medical Systems Oncology Systems Sales (Million US$), 2014 - 2018
Figure 10 4: Global - Forecast for Varian Medical Systems Oncology Systems Sales (Million US$), 2019 - 2025
Figure 10 5: Global - Elekta Revenue, (Million USD), 2014 - 2018
Figure 10 6: Global - Forecast for Elekta Revenue, (Million US$), 2019 - 2025
Figure 11 1: United States - Numbers of Patient Diagnosed With cancer (In Number), 2014 - 2018
Figure 11 2: United States - Forecast for Numbers of Patient Diagnosed With cancer (In Number), 2019 - 2025

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • IBA
  • Varian Medical Systems
  • Elekta
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll